Cabaletta Bio develops engineered T cell therapies for autoimmune diseases, with its lead candidate in clinical trials. CABA reports earnings on Mon, Nov 9, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 1 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 14 | Wells Fargo | Maintained | Hold |
Seasonality
How CABA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in CABA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CABA is in one of them and how their past CABA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CABA in an article yet. Here's the latest on the wider market.
About Cabaletta Bio
Cabaletta Bio is a biotechnology company based in Philadelphia, Pennsylvania, that develops engineered T cell therapies for people with autoimmune diseases. Its lead candidate, rese-cel, is a CAR T cell treatment designed to deplete B cells, and it is in clinical trials for conditions including myositis, lupus, systemic sclerosis and generalized myasthenia gravis. The company does not yet sell a commercial product, and the patients it aims to serve are people living with these conditions.
- Headquarters
- Philadelphia, PA